Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 33 | 2016 | 134 | 6.540 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 42 | 2017 | 458 | 6.250 |
Why?
|
Deoxycytidine | 28 | 2014 | 68 | 3.500 |
Why?
|
Camptothecin | 19 | 2014 | 51 | 2.930 |
Why?
|
Antineoplastic Agents | 18 | 2016 | 608 | 2.040 |
Why?
|
Colorectal Neoplasms | 13 | 2015 | 215 | 2.040 |
Why?
|
Lung Neoplasms | 20 | 2015 | 414 | 1.750 |
Why?
|
Adenocarcinoma | 12 | 2015 | 308 | 1.680 |
Why?
|
Neoplasms | 12 | 2016 | 729 | 1.360 |
Why?
|
Taxoids | 11 | 2017 | 59 | 1.290 |
Why?
|
Fluorouracil | 12 | 2014 | 81 | 1.260 |
Why?
|
Antimetabolites, Antineoplastic | 8 | 2010 | 49 | 1.210 |
Why?
|
Organoplatinum Compounds | 8 | 2014 | 46 | 1.110 |
Why?
|
Carcinoma, Small Cell | 8 | 2012 | 25 | 1.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 10 | 2006 | 101 | 1.100 |
Why?
|
Middle Aged | 57 | 2017 | 11839 | 0.950 |
Why?
|
Antibodies, Monoclonal | 10 | 2013 | 246 | 0.920 |
Why?
|
Aged | 52 | 2017 | 10314 | 0.910 |
Why?
|
Humans | 87 | 2017 | 32116 | 0.900 |
Why?
|
Paclitaxel | 5 | 2013 | 67 | 0.880 |
Why?
|
Adult | 44 | 2017 | 9381 | 0.800 |
Why?
|
Treatment Outcome | 27 | 2017 | 3306 | 0.760 |
Why?
|
Male | 56 | 2017 | 19218 | 0.730 |
Why?
|
Neoadjuvant Therapy | 7 | 2012 | 67 | 0.710 |
Why?
|
Salvage Therapy | 4 | 2011 | 134 | 0.710 |
Why?
|
Colonic Neoplasms | 3 | 2010 | 71 | 0.700 |
Why?
|
Female | 56 | 2017 | 20016 | 0.690 |
Why?
|
Chemotherapy, Adjuvant | 8 | 2015 | 190 | 0.690 |
Why?
|
Neoplasm Metastasis | 7 | 2014 | 220 | 0.690 |
Why?
|
Disease-Free Survival | 11 | 2017 | 317 | 0.650 |
Why?
|
Antineoplastic Agents, Phytogenic | 4 | 2005 | 37 | 0.650 |
Why?
|
Gastrointestinal Stromal Tumors | 5 | 2010 | 12 | 0.650 |
Why?
|
Drug Administration Schedule | 11 | 2016 | 276 | 0.620 |
Why?
|
Survival Analysis | 11 | 2014 | 483 | 0.600 |
Why?
|
Cancer Vaccines | 2 | 2014 | 24 | 0.580 |
Why?
|
Leucovorin | 3 | 2012 | 24 | 0.580 |
Why?
|
Indoles | 4 | 2016 | 56 | 0.580 |
Why?
|
Pyrroles | 4 | 2016 | 55 | 0.570 |
Why?
|
Aged, 80 and over | 24 | 2017 | 3990 | 0.560 |
Why?
|
Maximum Tolerated Dose | 10 | 2014 | 62 | 0.560 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2016 | 19 | 0.560 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2017 | 367 | 0.550 |
Why?
|
Carcinoma | 3 | 2012 | 91 | 0.550 |
Why?
|
Neoplasm Staging | 11 | 2014 | 447 | 0.540 |
Why?
|
Palliative Care | 2 | 2010 | 52 | 0.530 |
Why?
|
Protein Kinase Inhibitors | 3 | 2012 | 85 | 0.520 |
Why?
|
Endosonography | 4 | 2011 | 56 | 0.520 |
Why?
|
Topotecan | 4 | 2009 | 17 | 0.500 |
Why?
|
Angiogenesis Inhibitors | 3 | 2016 | 36 | 0.490 |
Why?
|
Gastrins | 1 | 2014 | 4 | 0.480 |
Why?
|
Stomach Neoplasms | 3 | 2014 | 84 | 0.460 |
Why?
|
Esophageal Neoplasms | 3 | 2011 | 35 | 0.450 |
Why?
|
Survival Rate | 15 | 2012 | 877 | 0.450 |
Why?
|
Albumins | 1 | 2013 | 45 | 0.430 |
Why?
|
Cell Cycle | 1 | 2012 | 77 | 0.410 |
Why?
|
Antimitotic Agents | 1 | 2012 | 2 | 0.410 |
Why?
|
Rectal Neoplasms | 2 | 2009 | 18 | 0.410 |
Why?
|
Oligopeptides | 1 | 2012 | 45 | 0.400 |
Why?
|
Clinical Trials as Topic | 6 | 2008 | 301 | 0.390 |
Why?
|
Piperidines | 2 | 2012 | 118 | 0.390 |
Why?
|
Biopsy, Fine-Needle | 4 | 2011 | 53 | 0.390 |
Why?
|
Biliary Tract Neoplasms | 2 | 2017 | 10 | 0.370 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2012 | 154 | 0.370 |
Why?
|
Cytoskeletal Proteins | 1 | 2010 | 15 | 0.370 |
Why?
|
Infusions, Intravenous | 5 | 2014 | 100 | 0.360 |
Why?
|
Drug Therapy | 1 | 2010 | 16 | 0.350 |
Why?
|
Biopsy, Needle | 2 | 2008 | 93 | 0.340 |
Why?
|
DNA Methylation | 1 | 2010 | 141 | 0.340 |
Why?
|
Prognosis | 9 | 2015 | 1497 | 0.330 |
Why?
|
Etoposide | 3 | 2007 | 34 | 0.330 |
Why?
|
CA-19-9 Antigen | 2 | 2013 | 6 | 0.320 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 21 | 0.310 |
Why?
|
Emphysematous Cholecystitis | 1 | 2007 | 1 | 0.290 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 104 | 0.290 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2007 | 12 | 0.290 |
Why?
|
Quinazolines | 4 | 2008 | 38 | 0.290 |
Why?
|
Ultrasonography, Interventional | 2 | 2011 | 53 | 0.290 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2012 | 104 | 0.270 |
Why?
|
Mediastinal Neoplasms | 1 | 2006 | 13 | 0.270 |
Why?
|
Ablation Techniques | 2 | 2016 | 25 | 0.260 |
Why?
|
Lymph Nodes | 1 | 2006 | 107 | 0.260 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2015 | 510 | 0.260 |
Why?
|
Electroporation | 2 | 2016 | 14 | 0.250 |
Why?
|
Combined Modality Therapy | 7 | 2010 | 560 | 0.240 |
Why?
|
Retrospective Studies | 11 | 2016 | 3510 | 0.240 |
Why?
|
Disease Progression | 5 | 2010 | 594 | 0.240 |
Why?
|
Coronary Vasospasm | 1 | 2004 | 4 | 0.230 |
Why?
|
Diarrhea | 3 | 2014 | 60 | 0.230 |
Why?
|
Hospitals, General | 1 | 2013 | 4 | 0.230 |
Why?
|
Cancer Care Facilities | 1 | 2013 | 10 | 0.230 |
Why?
|
Follow-Up Studies | 7 | 2014 | 2265 | 0.220 |
Why?
|
Drug Synergism | 3 | 2014 | 66 | 0.220 |
Why?
|
Liver Neoplasms | 3 | 2014 | 155 | 0.220 |
Why?
|
Carboplatin | 5 | 2007 | 48 | 0.210 |
Why?
|
Genetic Markers | 1 | 2002 | 124 | 0.200 |
Why?
|
Vomiting | 2 | 2014 | 24 | 0.170 |
Why?
|
Tomography, X-Ray Computed | 3 | 2016 | 919 | 0.170 |
Why?
|
Nausea | 2 | 2014 | 53 | 0.170 |
Why?
|
Pancreatic Diseases | 2 | 2010 | 18 | 0.170 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2010 | 40 | 0.170 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2011 | 31 | 0.160 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2002 | 30 | 0.160 |
Why?
|
European Continental Ancestry Group | 2 | 2014 | 1166 | 0.160 |
Why?
|
Piperazines | 2 | 2010 | 54 | 0.150 |
Why?
|
Pyrimidines | 2 | 2010 | 65 | 0.150 |
Why?
|
Pyridines | 2 | 2008 | 76 | 0.150 |
Why?
|
Endothelins | 1 | 2017 | 4 | 0.150 |
Why?
|
Brain Neoplasms | 1 | 2003 | 638 | 0.140 |
Why?
|
Radiography, Interventional | 1 | 2016 | 37 | 0.140 |
Why?
|
Epothilones | 1 | 2016 | 3 | 0.130 |
Why?
|
Tubulin Modulators | 1 | 2016 | 10 | 0.130 |
Why?
|
Young Adult | 4 | 2014 | 2666 | 0.130 |
Why?
|
African Americans | 2 | 2014 | 1425 | 0.130 |
Why?
|
Pancreatectomy | 2 | 2012 | 27 | 0.130 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2006 | 14 | 0.130 |
Why?
|
Splenic Artery | 1 | 2015 | 11 | 0.130 |
Why?
|
Thrombocytopenia | 1 | 2015 | 30 | 0.130 |
Why?
|
Breast Neoplasms | 3 | 2012 | 765 | 0.120 |
Why?
|
Neutropenia | 1 | 2014 | 29 | 0.120 |
Why?
|
Electrochemotherapy | 1 | 2014 | 3 | 0.120 |
Why?
|
Injections, Intramuscular | 1 | 2014 | 43 | 0.120 |
Why?
|
Embolization, Therapeutic | 1 | 2015 | 86 | 0.120 |
Why?
|
Sensitivity and Specificity | 4 | 2011 | 582 | 0.120 |
Why?
|
Peptide Fragments | 1 | 2017 | 399 | 0.120 |
Why?
|
Time Factors | 4 | 2016 | 2151 | 0.120 |
Why?
|
Perception | 1 | 2014 | 101 | 0.110 |
Why?
|
Immunohistochemistry | 2 | 2012 | 538 | 0.110 |
Why?
|
Pancreas | 2 | 2011 | 103 | 0.110 |
Why?
|
Receptor, erbB-2 | 1 | 2014 | 65 | 0.110 |
Why?
|
Quality of Life | 3 | 2004 | 946 | 0.110 |
Why?
|
Arsenic | 1 | 2013 | 3 | 0.110 |
Why?
|
Hematologic Diseases | 2 | 2004 | 23 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2010 | 24 | 0.110 |
Why?
|
Trisaccharides | 1 | 2012 | 1 | 0.110 |
Why?
|
Deoxyglucose | 1 | 2012 | 16 | 0.110 |
Why?
|
Immunotherapy, Active | 1 | 2012 | 6 | 0.110 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2012 | 9 | 0.110 |
Why?
|
Attitude to Health | 1 | 2014 | 166 | 0.110 |
Why?
|
Pancreaticoduodenectomy | 1 | 2012 | 20 | 0.110 |
Why?
|
Benzamides | 2 | 2010 | 50 | 0.110 |
Why?
|
Drug Design | 1 | 2012 | 43 | 0.110 |
Why?
|
Prospective Studies | 7 | 2014 | 2284 | 0.100 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2004 | 11 | 0.100 |
Why?
|
Environmental Exposure | 1 | 2013 | 91 | 0.100 |
Why?
|
Catheter Ablation | 1 | 2012 | 67 | 0.100 |
Why?
|
Adolescent | 4 | 2014 | 3569 | 0.100 |
Why?
|
Algorithms | 2 | 2012 | 495 | 0.100 |
Why?
|
Triazines | 1 | 2011 | 3 | 0.100 |
Why?
|
Boronic Acids | 2 | 2008 | 8 | 0.100 |
Why?
|
Alanine | 1 | 2011 | 27 | 0.100 |
Why?
|
Pyrazines | 2 | 2008 | 13 | 0.100 |
Why?
|
Cell Line, Tumor | 2 | 2010 | 726 | 0.100 |
Why?
|
Celiac Plexus | 1 | 2011 | 3 | 0.100 |
Why?
|
Diagnosis, Differential | 3 | 2010 | 517 | 0.090 |
Why?
|
Family | 1 | 2011 | 117 | 0.090 |
Why?
|
Metalloproteases | 1 | 2010 | 4 | 0.090 |
Why?
|
Diagnostic Imaging | 2 | 2008 | 94 | 0.090 |
Why?
|
CARD Signaling Adaptor Proteins | 1 | 2010 | 5 | 0.090 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2010 | 15 | 0.090 |
Why?
|
Abdominal Pain | 1 | 2011 | 44 | 0.090 |
Why?
|
Azacitidine | 1 | 2010 | 28 | 0.090 |
Why?
|
Gene Silencing | 1 | 2010 | 48 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2010 | 70 | 0.090 |
Why?
|
Mutation | 2 | 2010 | 489 | 0.090 |
Why?
|
Transfection | 1 | 2010 | 191 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2010 | 112 | 0.090 |
Why?
|
Caregivers | 1 | 2011 | 114 | 0.090 |
Why?
|
Biliary Tract Diseases | 1 | 2010 | 12 | 0.090 |
Why?
|
Cisplatin | 3 | 2011 | 76 | 0.090 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2010 | 32 | 0.090 |
Why?
|
Promoter Regions, Genetic | 1 | 2010 | 208 | 0.090 |
Why?
|
Radiation Tolerance | 1 | 2009 | 24 | 0.090 |
Why?
|
Proteins | 1 | 2010 | 144 | 0.080 |
Why?
|
Models, Genetic | 1 | 2009 | 94 | 0.080 |
Why?
|
Lymphatic Metastasis | 2 | 2007 | 166 | 0.080 |
Why?
|
Benzenesulfonates | 1 | 2008 | 3 | 0.080 |
Why?
|
Phenylurea Compounds | 1 | 2008 | 10 | 0.080 |
Why?
|
Niacinamide | 1 | 2008 | 8 | 0.080 |
Why?
|
Gene Expression | 1 | 2009 | 338 | 0.080 |
Why?
|
Depression | 1 | 2011 | 445 | 0.080 |
Why?
|
DNA Topoisomerases, Type I | 2 | 2006 | 9 | 0.080 |
Why?
|
Endoscopy | 1 | 2008 | 58 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2009 | 130 | 0.080 |
Why?
|
Patient Care Team | 1 | 2008 | 129 | 0.070 |
Why?
|
Administration, Oral | 2 | 2007 | 187 | 0.070 |
Why?
|
Cholecystostomy | 1 | 2007 | 1 | 0.070 |
Why?
|
Hyperbilirubinemia | 1 | 2007 | 2 | 0.070 |
Why?
|
Leukocytosis | 1 | 2007 | 7 | 0.070 |
Why?
|
Phosphorylcholine | 1 | 2007 | 5 | 0.070 |
Why?
|
Probability | 1 | 2007 | 159 | 0.070 |
Why?
|
Radiography | 2 | 2012 | 376 | 0.070 |
Why?
|
Risk Factors | 2 | 2014 | 3880 | 0.070 |
Why?
|
Proportional Hazards Models | 3 | 2016 | 753 | 0.070 |
Why?
|
Acute Disease | 1 | 2007 | 253 | 0.070 |
Why?
|
Feasibility Studies | 1 | 2007 | 294 | 0.070 |
Why?
|
Sarcoma | 1 | 2007 | 73 | 0.070 |
Why?
|
Equipment Design | 1 | 2006 | 171 | 0.070 |
Why?
|
Models, Statistical | 1 | 2006 | 175 | 0.060 |
Why?
|
Alkyl and Aryl Transferases | 1 | 2004 | 2 | 0.060 |
Why?
|
Thalidomide | 1 | 2005 | 31 | 0.060 |
Why?
|
Quinolones | 1 | 2004 | 7 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2010 | 633 | 0.060 |
Why?
|
Electrocardiography | 2 | 2012 | 605 | 0.060 |
Why?
|
Enterocolitis, Neutropenic | 1 | 2004 | 1 | 0.060 |
Why?
|
Aniline Compounds | 1 | 2014 | 18 | 0.060 |
Why?
|
Patient Selection | 2 | 2007 | 276 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 34 | 0.060 |
Why?
|
Imidazoles | 1 | 2004 | 91 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2007 | 324 | 0.060 |
Why?
|
Signal Transduction | 1 | 2008 | 682 | 0.060 |
Why?
|
Lymphocytes | 1 | 2004 | 57 | 0.060 |
Why?
|
Sulfonamides | 1 | 2014 | 67 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 166 | 0.060 |
Why?
|
Hospitals, Voluntary | 1 | 2013 | 2 | 0.060 |
Why?
|
Epidermal Growth Factor | 1 | 2003 | 27 | 0.060 |
Why?
|
Blood-Brain Barrier | 1 | 2003 | 48 | 0.050 |
Why?
|
SEER Program | 3 | 2007 | 30 | 0.050 |
Why?
|
Survival | 1 | 2002 | 13 | 0.050 |
Why?
|
Poverty | 1 | 2013 | 115 | 0.050 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2002 | 6 | 0.050 |
Why?
|
Safety | 1 | 2002 | 77 | 0.050 |
Why?
|
Age Distribution | 1 | 2002 | 206 | 0.050 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2001 | 22 | 0.050 |
Why?
|
Stress, Psychological | 2 | 2014 | 222 | 0.050 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2001 | 24 | 0.050 |
Why?
|
Hematologic Neoplasms | 1 | 2001 | 35 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2014 | 770 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2000 | 105 | 0.050 |
Why?
|
Florida | 2 | 2013 | 37 | 0.040 |
Why?
|
Area Under Curve | 2 | 2010 | 93 | 0.040 |
Why?
|
Tumor Burden | 1 | 2016 | 58 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2010 | 765 | 0.030 |
Why?
|
Incidence | 2 | 2013 | 1199 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2016 | 82 | 0.030 |
Why?
|
Registries | 2 | 2007 | 298 | 0.030 |
Why?
|
Georgia | 1 | 2014 | 14 | 0.030 |
Why?
|
Family Relations | 1 | 2014 | 23 | 0.030 |
Why?
|
Epirubicin | 1 | 2014 | 1 | 0.030 |
Why?
|
Water Supply | 1 | 2013 | 10 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 163 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 45 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2013 | 125 | 0.030 |
Why?
|
Receptor, IGF Type 1 | 1 | 2012 | 7 | 0.030 |
Why?
|
Placebos | 1 | 2012 | 63 | 0.030 |
Why?
|
Rare Diseases | 1 | 2012 | 21 | 0.030 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 148 | 0.030 |
Why?
|
Esophagogastric Junction | 1 | 2011 | 7 | 0.020 |
Why?
|
Aneuploidy | 1 | 2011 | 10 | 0.020 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2011 | 13 | 0.020 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2011 | 16 | 0.020 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2011 | 15 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2011 | 40 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2011 | 40 | 0.020 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2011 | 28 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 23 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2011 | 61 | 0.020 |
Why?
|
Autonomic Nerve Block | 1 | 2011 | 10 | 0.020 |
Why?
|
Analgesia | 1 | 2011 | 29 | 0.020 |
Why?
|
Logistic Models | 1 | 2013 | 783 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2011 | 288 | 0.020 |
Why?
|
Social Support | 1 | 2011 | 182 | 0.020 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 2010 | 3 | 0.020 |
Why?
|
Half-Life | 1 | 2010 | 23 | 0.020 |
Why?
|
Biliary Tract | 1 | 2010 | 7 | 0.020 |
Why?
|
Blood Glucose | 1 | 2012 | 494 | 0.020 |
Why?
|
Pain Measurement | 1 | 2011 | 350 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2009 | 160 | 0.020 |
Why?
|
Sample Size | 1 | 2008 | 38 | 0.020 |
Why?
|
Linear Models | 1 | 2009 | 449 | 0.020 |
Why?
|
United States | 2 | 2007 | 3976 | 0.020 |
Why?
|
Muscle Neoplasms | 1 | 2007 | 8 | 0.020 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2007 | 25 | 0.020 |
Why?
|
Muscle, Smooth | 1 | 2007 | 68 | 0.020 |
Why?
|
Antiemetics | 1 | 2007 | 6 | 0.020 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2006 | 4 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2007 | 111 | 0.020 |
Why?
|
Population Surveillance | 1 | 2007 | 125 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2008 | 898 | 0.020 |
Why?
|
Farnesyltranstransferase | 1 | 2004 | 2 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2007 | 684 | 0.020 |
Why?
|
Inhibitory Concentration 50 | 1 | 2004 | 22 | 0.020 |
Why?
|
Models, Chemical | 1 | 2004 | 34 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2004 | 56 | 0.010 |
Why?
|
Flavonoids | 1 | 2004 | 18 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2004 | 83 | 0.010 |
Why?
|
Peritoneal Neoplasms | 1 | 2007 | 259 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2007 | 881 | 0.010 |
Why?
|
Cohort Studies | 1 | 2007 | 1817 | 0.010 |
Why?
|
Vinblastine | 1 | 2000 | 6 | 0.010 |
Why?
|
Remission Induction | 1 | 2000 | 84 | 0.010 |
Why?
|
Child | 1 | 2007 | 2442 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1999 | 171 | 0.010 |
Why?
|